Tech Company Financing Transactions
ImmusanT Funding Round
ImmusanT, based in Cambridge, secured $40 million in investment from Arch Venture Partners and Vatera Healthcare Partners.
Transaction Overview
Company Name
Announced On
11/15/2017
Transaction Type
Venture Equity
Amount
$40,000,000
Round
Series C
Investors
Arch Venture Partners (Steven Gillis)
Vatera Healthcare Partners (Kevin Ferro)
Proceeds Purpose
The proceeds will fund a randomized Phase II clinical trial of escalating doses of Nexvax2 in celiac patients who possess the human leukocyte antigen-DQ2.5 (HLA-DQ2.5) immune recognition gene. Funds will also be used for the continued advancement of the company's diagnostic biomarker program and platform expansion.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1 Kendall Sq. Building 700
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Website
Email Address
Overview
ImmusanT is a biotechnology company focused on developing a treatment, and a set of diagnostic and monitoring tools to manage patients with celiac disease.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Leslie Williams
Chief Medical Officer
Kenneth Truitt
Chief Scientific Officer
Robert Anderson
Vice President
Joyce Pinkham
VP - Bus. Development
Matan Dabora
VP - Finance
Jonathan Yeadon
VP - Operations
Kristin Neff
Browse more venture capital transactions:
Prev: 11/15/2017: CleanCapital venture capital transaction
Next: 11/16/2017: GenomeDx Biosciences venture capital transaction
Share this article
News on VC Transactions
Our team works diligently to document every notable VC transaction. VC investment data records reported here are sourced from a variety of public sources. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs